{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T11:26:58Z","timestamp":1772105218980,"version":"3.50.1"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1093\/jac\/dkn048","type":"journal-article","created":{"date-parts":[[2008,2,20]],"date-time":"2008-02-20T03:37:43Z","timestamp":1203478663000},"page":"1125-1131","source":"Crossref","is-referenced-by-count":22,"title":["In vivo distribution and therapeutic efficacy of a novel amphotericin B poly-aggregated formulation"],"prefix":"10.1093","volume":"61","author":[{"given":"R.","family":"Espada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Valdespina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Dea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Molero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. P.","family":"Ballesteros","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Bol\u00e1s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J. J.","family":"Torrado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2008,2,19]]},"reference":[{"key":"key\n\t\t\t\t20170425170917_DKN048C1","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1086\/313749","article-title":"Practice guidelines for the treatment of candidiasis","volume":"30","author":"Rex","year":"2000","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425170917_DKN048C2","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1046\/j.1523-1755.2001.00948.x","article-title":"Correlates of acute renal failure in patients receiving parenteral amphotericin B","volume":"60","author":"Bates","year":"2001","journal-title":"Kidney Int"},{"key":"key\n\t\t\t\t20170425170917_DKN048C3","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkh460","article-title":"Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis","volume":"54","author":"Adler-Moore","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C4","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1128\/CMR.9.4.512","article-title":"Carrier effects on biological activity of amphotericin B","volume":"9","author":"Brajtburg","year":"1996","journal-title":"Clin Microbiol Rev"},{"key":"key\n\t\t\t\t20170425170917_DKN048C5","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1034\/j.1399-3062.1999.010406.x","article-title":"Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability","volume":"1","author":"Tiphine","year":"1999","journal-title":"Transpl Infect Dis"},{"key":"key\n\t\t\t\t20170425170917_DKN048C6","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic-pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C7","doi-asserted-by":"crossref","first-page":"441","DOI":"10.2174\/1381612023395853","article-title":"Pharmaceutical design of the liposomal antimicrobial agents for infectious disease","volume":"8","author":"Moribe","year":"2002","journal-title":"Curr Pharm Design"},{"key":"key\n\t\t\t\t20170425170917_DKN048C8","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1002\/jps.10065","article-title":"Amphotericin B in oil-water lecithin-based microemulsions: formulation and toxicity evaluation","volume":"91","author":"Brime","year":"2002","journal-title":"J Pharm Sci"},{"key":"key\n\t\t\t\t20170425170917_DKN048C9","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0076-6879(05)91018-5","article-title":"Drug delivery by lipid cochleates","volume":"391","author":"Zarif","year":"2005","journal-title":"Methods Enzymol"},{"key":"key\n\t\t\t\t20170425170917_DKN048C10","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1093\/jac\/dki455","article-title":"Water-soluble amphotericin B-polyvinylpyrrolidone complexes with maintained antifungal activity against Candida spp. and Aspergillus spp. and reduced haemolytic and cytotoxic effects","volume":"57","author":"Charvalos","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C11","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1080\/10611860500097107","article-title":"Influence of the vehicle on the properties and efficacy of microparticles containing amphotericin B","volume":"13","author":"S\u00e1nchez-Brunete","year":"2005","journal-title":"J Drug Target"},{"key":"key\n\t\t\t\t20170425170917_DKN048C12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0378-5173(02)00686-5","article-title":"Formulation of amphotericin B as nanosuspensions for oral administration","volume":"254","author":"Kayser","year":"2003","journal-title":"Int J Pharm"},{"key":"key\n\t\t\t\t20170425170917_DKN048C13","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1093\/jac\/dkg351","article-title":"Polymeric carriers of amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice","volume":"52","author":"Espuelas","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0301-4622(96)02241-7","article-title":"Physicochemical properties of the heat-induced superaggregates of amphotericin B","volume":"66","author":"Gaboriau","year":"1997","journal-title":"Biophys Chem"},{"key":"key\n\t\t\t\t20170425170917_DKN048C15","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1093\/oxfordjournals.jbchem.a022007","article-title":"Interaction of amphotericin B with cholesterol in monolayers, aqueous solutions, and phospholipid bilayers","volume":"123","author":"Saka","year":"1998","journal-title":"J Biochem"},{"key":"key\n\t\t\t\t20170425170917_DKN048C16","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/0005-2736(90)90305-8","article-title":"The effect of surfactants on the aggregation state of amphotericin B","volume":"1030","author":"Tancr\u00e8de","year":"1990","journal-title":"Biochim Biophys Acta"},{"key":"key\n\t\t\t\t20170425170917_DKN048C17","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1021\/bm0257614","article-title":"Amphotericin B encapsulated in micelles based on poly(ethylene oxide)-block-poly(l-amino acid) derivatives exerts reduced in vitro hemolysis but maintains potent in vivo antifungal activity","volume":"4","author":"Adams","year":"2003","journal-title":"Biomacromolecules"},{"key":"key\n\t\t\t\t20170425170917_DKN048C18","first-page":"386","article-title":"PEG-phospholipid micelles for the delivery of amphotericin B","volume":"101","author":"Vakil","year":"2005","journal-title":"J Control Release"},{"key":"key\n\t\t\t\t20170425170917_DKN048C19","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1080\/10611860400006596","article-title":"Amphotericin B molecular organization as an essential factor to improve activity\/toxicity ratio in the treatment of visceral leishmaniasis","volume":"12","author":"Sanchez-Brunete","year":"2004","journal-title":"J Drug Target"},{"key":"key\n\t\t\t\t20170425170917_DKN048C20","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1128\/AAC.48.1.333-336.2004","article-title":"Effect of heat-treated amphotericin B on renal and fungal cytotoxicity","volume":"48","author":"Barlett","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C21","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1128\/AAC.44.6.1598-1603.2000","article-title":"Mild heating of amphotericin B-deoxycholate: effects on ultrastructure, in vitro activity and toxicity, and therapeutic efficacy in severe candidiasis in leukopenic mice","volume":"44","author":"van Etten","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C22","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1128\/AAC.41.11.2345","article-title":"Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index","volume":"41","author":"Gaboriau","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C23","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1093\/jac\/42.6.779","article-title":"In vivo therapeutic efficacy in experimental murine mycoses of a new formulation of deoxycholate-amphotericin B (Fungizone) obtained by mild heating","volume":"42","author":"Petit","year":"1998","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C24","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1128\/AAC.43.2.390","article-title":"Activity of a heat-induced reformulation of amphotericin B deoxycholate (Fungizone) against Leishmania donovani","volume":"43","author":"Petit","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C25","doi-asserted-by":"crossref","first-page":"3246","DOI":"10.1128\/AAC.48.9.3246-3252.2004","article-title":"Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres","volume":"48","author":"S\u00e1nchez-Brunete","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C26","volume-title":"Applied Biopharmaceutics and Pharmacokinetics","author":"Shargel","year":"1993","edition":"3rd ed."},{"key":"key\n\t\t\t\t20170425170917_DKN048C27","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1007\/BF00328721","article-title":"Isolation of the Candida albicans gene for orotidine-5\u2032-phosphate decarboxylaseby complementation of S. cerevisiae ura3 and E. coli pyrF mutations","volume":"198","author":"Gillum","year":"1984","journal-title":"Mol Gen Genet"},{"key":"key\n\t\t\t\t20170425170917_DKN048C28","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.ejps.2004.04.008","article-title":"Comparative therapeutic efficacy of a novel lyophilized amphotericin B lecithin-based oil-water microemulsion and deoxycholate-amphotericin B in immunocompetent and neutropenic mice infected with Candida albicans","volume":"22","author":"Brime","year":"2004","journal-title":"Eur J Pharm Sci"},{"key":"key\n\t\t\t\t20170425170917_DKN048C29","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/path.1711500405","article-title":"The pathogenesis of acute systemic candidiasis in a susceptible inbred mice strain","volume":"150","author":"Papadimitriou","year":"1986","journal-title":"J Pathol"},{"key":"key\n\t\t\t\t20170425170917_DKN048C30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/j.1439-0507.1988.tb03867.x","article-title":"Kidney function in experimental systemic candidosis of mice","volume":"31","author":"Ryley","year":"1988","journal-title":"Mycoses"},{"key":"key\n\t\t\t\t20170425170917_DKN048C31","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1093\/jac\/dkg455","article-title":"Heat-induced reformulation of amphotericin B-deoxycholate favours drug uptake by the macrophage-like cell line J774","volume":"52","author":"Cheron","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C32","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1023\/A:1007605024942","article-title":"Safety, toxicokinetics and tissue distribution of long-term intravenous liposomal amphotericin B (AmBisome): A 91-day study in rats","volume":"17","author":"Bekersky","year":"2000","journal-title":"Pharm Res"},{"key":"key\n\t\t\t\t20170425170917_DKN048C33","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1128\/AAC.42.2.263","article-title":"Toxicological profile and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B in rats","volume":"42","author":"Boswell","year":"1998","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C34","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1128\/AAC.44.4.898-904.2000","article-title":"Comparative pharmacokinetics, tissue distributions, and effects on renal function of novel polymeric formulations of amphotericin B and amphotericin b-deoxycholate in rats","volume":"44","author":"Echevarr\u00eda","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C35","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"key\n\t\t\t\t20170425170917_DKN048C36","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1128\/AAC.45.7.2060-2063.2001","article-title":"Heat treatment of amphotericin B modifies its serum pharmacokinetics, tissue distribution, and renal toxicity following administration of a single intravenous dose to rabbits","volume":"45","author":"Kwong","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"key\n\t\t\t\t20170425170917_DKN048C37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S1130-1406(06)70045-6","article-title":"Prevalence of fungal infections detected from biopsies and autopsies in the past 11 years at the University Hospital Joan XXIII in Tarragona, Spain","volume":"23","author":"Garc\u00eda-Fontgivell","year":"2006","journal-title":"Rev Iberoam Micol"},{"key":"key\n\t\t\t\t20170425170917_DKN048C38","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.ijantimicag.2006.03.013","article-title":"What is the current and future status of conventional amphotericin B?","volume":"27S","author":"Kleinberg","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"key\n\t\t\t\t20170425170917_DKN048C39","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1185\/030079904125003179","article-title":"Efficacy, safety and cost-effectiveness of amphotericin B lipid complex (ABLC): a review of the literature","volume":"20","author":"Martino","year":"2004","journal-title":"Curr Med Res Opin"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jac\/article-pdf\/61\/5\/1125\/13758941\/dkn048.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,2]],"date-time":"2020-05-02T03:12:29Z","timestamp":1588389149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article-lookup\/doi\/10.1093\/jac\/dkn048"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,2,19]]},"references-count":39,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2008,2,19]]},"published-print":{"date-parts":[[2008,5]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkn048","relation":{},"ISSN":["1460-2091","0305-7453"],"issn-type":[{"value":"1460-2091","type":"electronic"},{"value":"0305-7453","type":"print"}],"subject":[],"published":{"date-parts":[[2008,2,19]]}}}